Ionis slashes key drug revenue outlook by 50%, shares fall despite solid earnings
FROM THE WIRE · BARRONS.COM
Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA steep cut to guidance on a flagship drug weighs on the stock even though the earnings were otherwise solid.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Ionis cut full-year revenue guidance for one of its flagship drugs by 50%.
- 02Shares sank after the announcement.
- 03Overall earnings were described as solid.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets